AURORA CANNABIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.66 EUR | -1.65% |
|
-8.71% | +27.11% |
| 05-16 | US Government Reclassifies Marijuana to Less-Restrictive Category | MT |
| 05-16 | Justice Department Set to Post Cannabis Reclassification Plans | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +27.11% | 337M | - | ||
| +37.29% | 6.02B | B- | ||
| -21.28% | 4.19B | C+ | ||
| +4.52% | 3.25B | C | ||
| -18.16% | 2.87B | B- | ||
| -7.70% | 2.37B | - | D+ | |
| +41.50% | 1.89B | - | ||
| -4.05% | 1.58B | - | - | |
| -15.56% | 1.54B | - | - | |
| -14.62% | 1.5B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ACB Stock
- 21P Stock
- Ratings Aurora Cannabis Inc.
